In gratitude of the loyal support of our members, the CNS is offering complimentary 2021 Annual Meeting registration to all members! Learn more.

  • The Role of Magnetic Resonance-Guided Laser Ablation for Intracranial Metastatic Tumors

    Final Number:
    1622

    Authors:
    Michael E. Ivan MD, MBS; Nicholas Ferraro MD; Mike H Berger; Christopher Banerjee; Brian Michael Snelling MD; Amanda Wallo; Ricardo Jorge Komotar MD, FAANS

    Study Design:
    Other

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2015 Annual Meeting

    Introduction: Magnetic resonance-guided laser-induced thermotherapy(MR-LITT) is a minimally invasive technique that shows promise in neuro-oncology due to its superiority in delivering precise minimally invasive thermal energy with minimal collateral damage. In this analysis we investigate initial data on its effect on brain metastases.

    Methods: 16 patients were identified over a 2 year period with intracranial metastases with clear evidence of radiological progression. All patients received MR-LITT and then a follow-up MRI scan at 24 hours post treatment, at one month, and at each subsequent follow up visit. The primary end point of the study was local control of the ablated tumor and overall survival. Secondary endpoints include reporting the volume changes after LITT, steroid usage, and symptomatic relief.

    Results: 16 LITT treatments were performed with the average age of 57.2years. All lesions were treated with prior radiosurgery. The average tumor volume was 4.0cm3 and ablation dosage was 12.3Watts. In total, 90.2% of the pretreatment lesion volume was ablated. The mean follow-up time was 28 weeks. In total, 9 patients died, 2 due to aspiration pneumonia and 7 due to extracranial disease progression. 12 of 16 patients showed no local disease progression. Interesting, only 1 patient with >85% of tumor ablation had progression (p=0.01). There were no major complications.

    Conclusions: MR-LITT is a promising technology for cerebral metastases resistant to radiosurgery. This initial study demonstrates that MR-LITT is safe and offers several advantages over open surgical treatment. Randomized studies are needed to evaluate its role as a treatment adjunct.

    Patient Care: Understand the saftey and efficacy of LITT therapy with metastatic intracranial lesions.

    Learning Objectives: Understand the saftey and efficacy of LITT therapy with metastatic intracranial lesions.

    References:

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy